Using DNA nanostructures to improve drug delivery and biosensing
Official title: Programmable DNA Nanostructures as Biomedical and Structural Scaffolds
Funded at State University of New York at Albany · NIH-10895409 · Data updated 2026-11-12
This study is working on a new way to use tiny DNA structures to deliver medicines more effectively to treat conditions like myotonic dystrophy type 1, helping to improve how well these treatments work in the body.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | State University of New York at Albany NIH-funded |
| Lab location | 1 site (Albany, United States) |
| Project start | August 1, 2023 |
| Project end | July 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $391,250 |
| NIH project number | 5R35GM150672-02 |
| Project ID | NIH-10895409 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with myotonic dystrophy type 1 or other multisystemic diseases that could benefit from advanced drug delivery methods.
✕Less likely to help
Patients with conditions unrelated to drug delivery or those not affected by multisystemic diseases may not receive any benefit from this research.
What this research studies
This research focuses on developing programmable DNA nanostructures that can precisely position therapeutic molecules, such as drugs and antibodies, for various biomedical applications. The project aims to create a multifunctional drug delivery system specifically targeting multisystemic diseases, using myotonic dystrophy type 1 as a model. Additionally, it explores the use of 3D DNA crystals as scaffolds for advanced imaging techniques to better understand molecular structures. By validating the efficiency of these DNA-based systems in cell cultures and preclinical models, the research seeks to enhance drug bioavailability and targeting.
Why it matters
Potential benefit: If successful, this research could lead to more effective and targeted drug delivery systems, improving treatment outcomes for patients with complex diseases.
How similar studies have gone: While DNA nanotechnology is a rapidly evolving field, this specific approach to drug delivery and biosensing is relatively novel and has not been extensively tested in clinical settings.
Where this research is happening
-
State University of New York at Albany
Albany, United States Active
Researchers
- Principal investigator: Chandrasekaran, Arun Richard — State University of New York at Albany
- Study coordinator: Chandrasekaran, Arun Richard
Related research
Other NIH-funded projects on the same topics.
-
Cross-disease small molecule therapy for CAG expansion spinocerebellar ataxias
A new NIH grant is exploring whether existing and natural small molecules can lower harmful CAG RNA and proteins across several spinocerebellar ataxias to help people with these conditions.
-
New small molecule therapeutics to help myotonic dystrophy
A new NIH-funded project tests specially designed small molecules to lower harmful RNA activity in myotonic dystrophy and related diseases, aiming to reduce disease-driving RNA effects.
-
Biofilm structure and its role in the start of gum disease
A researchers team will study how tiny communities of bacteria at the gumline interact with the mouth’s tissues to spark inflammation that leads from healthy gums to periodontal disease.
-
Understanding how unusual RNA translation happens in neurological diseases
Researchers are studying how RNAs can start making proteins in unexpected ways in neurodegenerative diseases, which could reveal new targets for therapy.
-
Early-life neighborhood redlining and lifetime mortality in a historical cohort
This project looks at whether growing up in areas graded or disinvested by HOLC in the 1930s affects mortality later in life for people born in 1930–1940.
-
Activating PTP1B and Other Phosphatases with Small Molecules
A safety-focused, patient-friendly look at a project that aims to turn on natural enzymes in our cells to help correct harmful signals in diseases.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.